![Figure 4 from EVALUATION OF THE EFFICACY AND SAFETY OF 0.05% HALOBETASOL PROPIONATE OINTMENT AND 0.05% CLOBETASOL PROPIONATE OINTMENT IN CHRONIC, LOCALIZED PLAQUE PSORIASIS | Semantic Scholar Figure 4 from EVALUATION OF THE EFFICACY AND SAFETY OF 0.05% HALOBETASOL PROPIONATE OINTMENT AND 0.05% CLOBETASOL PROPIONATE OINTMENT IN CHRONIC, LOCALIZED PLAQUE PSORIASIS | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8a7891caf4a7e96806e839ad913f2850b10c7ad4/3-Figure4-1.png)
Figure 4 from EVALUATION OF THE EFFICACY AND SAFETY OF 0.05% HALOBETASOL PROPIONATE OINTMENT AND 0.05% CLOBETASOL PROPIONATE OINTMENT IN CHRONIC, LOCALIZED PLAQUE PSORIASIS | Semantic Scholar
![Topical Clobetasol Propionate Treatment and Cutaneous Adverse Effects in Patients With Early-Stage Mycosis Fungoides: An Observational Study | MDedge Dermatology Topical Clobetasol Propionate Treatment and Cutaneous Adverse Effects in Patients With Early-Stage Mycosis Fungoides: An Observational Study | MDedge Dermatology](https://cdn.mdedge.com/files/s3fs-public/CT105005027_e_Fig2ABC.jpg)
Topical Clobetasol Propionate Treatment and Cutaneous Adverse Effects in Patients With Early-Stage Mycosis Fungoides: An Observational Study | MDedge Dermatology
![Topical Clobetasol Propionate Treatment and Cutaneous Adverse Effects in Patients With Early-Stage Mycosis Fungoides: An Observational Study | MDedge Dermatology Topical Clobetasol Propionate Treatment and Cutaneous Adverse Effects in Patients With Early-Stage Mycosis Fungoides: An Observational Study | MDedge Dermatology](https://cdn.mdedge.com/files/s3fs-public/CT105005027_e_Fig1AB.jpg)